US Cancer Vaccine Pipeline Analysis
|出版日期||內容資訊||英文 300 Pages
|美國的癌症疫苗的開發平台分析 US Cancer Vaccine Pipeline Analysis|
|出版日期: 2014年01月14日||內容資訊: 英文 300 Pages||
Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Merck's Gardasil, a Prophylactic cancer vaccine, along with GSK's Cervarix are some of the first vaccines to have gained attention globally with their blockbuster status.
The market for cancer vaccine is in its growth stage in the US and has great opportunities for entry. Constituting almost 50% of the global pie, the US cancer vaccine market was estimated to be worth USD 14 Billion in 2012. With close to 1.5 million Americans being diagnosed with cancer every year, this market is expected to o reach USD 20 billion by 2020.
"US Cancer Vaccine Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various vaccines being developed for the treatment of various cancers. Research report covers all vaccines being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US cancer vaccine market based upon development process.
Following parameters for each orphan designated drug profile in development phase are covered in "US Cancer Vaccine Pipeline Analysis" research report:
US Cancer Vaccine Pipeline by Clinical Phase:
Each Drug Profile has Tables Representing Following Information: